RxDoctor Payments Data

Sherwonna Barron, APRN

Nurse Practitioner · Woodridge, ILNPI 1477229334

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 25 payments — averaging $47.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$711
  • Urovant Sciences Inc$225
  • Cardiovascular Systems Inc.$151
  • Alpha Cognition USA, Inc.$54
  • Smith+Nephew$23
  • AstraZeneca$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.15$711
Urovant Sciences Inc5$225
Cardiovascular Systems Inc.1$151
Alpha Cognition USA, Inc.1$54
Smith+Nephew1$23
AstraZeneca1$16
Exact Sciences1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$209,812
Medicare patients
531
Services billed
3,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$99,641
EliquisApixaban84$25,148
JardianceEmpagliflozin18$4,548
TradjentaLinagliptin14$3,780
Levothyroxine Sodium56$1,859
Atorvastatin Calcium60$1,230
Lacosamide22$1,156
Amlodipine Besylate110$887
Finasteride27$748
Memantine Hcl110$429
Phenytoin11$423
Metformin Hcl88$397
Phenobarbital16$364
Donepezil Hcl118$298
Tamsulosin Hcl19$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$711$99,64113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Woodridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →